白三烯受体拮抗剂治疗儿童哮喘的疗效观察

目的探讨孟鲁司特在儿童哮喘中的应用及疗效。方法将97例哮喘患儿随机分为常规治疗组48例和常规治疗加用孟鲁司特组49例,观察患儿急性期症状消失的时间及最大呼气流量(PEF)升高的幅度及各级哮喘患儿6个月内累积吸入糖皮质激素的总量及速效受体激动剂的总量,并比较两组患儿升降级治疗的例数。结果两组哮喘患儿急性期临床症状、体征消失时间比较差异无显著性(P>0.05),两组间PEF的改善幅度比较在一级哮喘患儿差异无显著性(P>0.05),而在二、三级哮喘患儿差异有显著性(P<0.05),对于吸入糖皮质激素和吸入速效受体激动剂用量的比较,同样在一级哮喘患儿差异无显著性(P>0.05),而在二、三级哮喘患儿孟鲁司特组用量明显少于对照组(P<0.05)。同时在对照组的二、三级患儿分别有35.3%(6/18)和25.0%(3/12)降级治疗,而在孟鲁司特组的数据为57.9%(11/19)和53.8%(7/13)。结论对于轻度持续和中度持续的哮喘患儿,加用孟鲁司特有助于缓解病情,减少糖皮质激素和β2受体激动剂的用量,而对于轻度间歇的哮喘患儿无明显帮助

The Clinical Observation of Childhood Asthma Treated Leukotriene Receptor Antagonist

Objective To discussion the application and efficacy of childhood asthma treated by montelukast. Method 97 cases of children with asthma will be randomly divided into 48 cases of conventional therapy group and conventional therapy plus montelukast group with 49 cases, and to observed in children with symptoms of acute time period and the maximal expiratory flow （PEF） increased the magnitude and class children with asthma within 6 months the cumulative inhaled corticosteroids and the total amount of the total amount of available receptor agonist, and compare the two-class treatment in children with take-off and landing a few cases. Result Two groups of asthmatic children in acute phase clinical symptoms and signs disappear time there was no significant difference （P〉 0.05）, improvement in PEF between the two groups to compare the primary-class asthma children there was no significant difference （P〉 0.05）, while in secondary and tertiary-class children with asthma there was a significant difference （P〈 0.05）; for inhalation and inhaled glucocorticoid receptor agonist dosage quick comparison, in primary-class asthma children there was no significant difference （P〉 0.05）, but in secondary and tertiary-class children with asthma montelukast group significantly less than the amount of the control group （P〈 0.05）. At the same time, in the control group of secondary and tertiary-class children with asthma were 35.3% （6/18） and 25.0% （3/12） demotion treatment, and in the montelukast group data for 57.9% （11/19） and 53.8 % （7/13）. Conclusion For mild persistent and moderate persistent children with asthma, montelukast added to help alleviate the condition and reduce glueocorticoid receptor agonist and the amount of β2 receptor antagonist, and for children with mild intermittent asthma had no significant curative effect.